<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://emdrive.echothis.com/index.php?action=history&amp;feed=atom&amp;title=Uses_Side_Impacts_Interactions_Pictures_Warnings_Application.</id>
	<title>Uses Side Impacts Interactions Pictures Warnings Application. - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://emdrive.echothis.com/index.php?action=history&amp;feed=atom&amp;title=Uses_Side_Impacts_Interactions_Pictures_Warnings_Application."/>
	<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=Uses_Side_Impacts_Interactions_Pictures_Warnings_Application.&amp;action=history"/>
	<updated>2026-09-12T07:40:37Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.41.1</generator>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=Uses_Side_Impacts_Interactions_Pictures_Warnings_Application.&amp;diff=455682&amp;oldid=prev</id>
		<title>BernadetteHornib at 09:59, 22 August 2024</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=Uses_Side_Impacts_Interactions_Pictures_Warnings_Application.&amp;diff=455682&amp;oldid=prev"/>
		<updated>2024-08-22T09:59:50Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 02:59, 22 August 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Tell &lt;/del&gt;your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;healthcare provider immediately if you &lt;/del&gt;(or your youngster)&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;: may not be seeing as well as before starting SABRIL; start to trip&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;run across points&lt;/del&gt;, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;or are more awkward than normal &lt;/del&gt;[https://&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;atavi&lt;/del&gt;.com/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;share&lt;/del&gt;/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;wpqxlqz14kk1s &lt;/del&gt;vigabatrin &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;side effects in babies&lt;/del&gt;]&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;; are shocked by things &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;people coming in front &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;you that appear &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;come out &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;no place; &lt;/del&gt;or &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;if your child is acting in different ways than typical&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The Vigabatrin REMS Program is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;called for &lt;/del&gt;by the FDA to make certain &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;informed &lt;/del&gt;risk-benefit &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;decisions &lt;/del&gt;prior to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;launching &lt;/del&gt;therapy, and to make &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;certain appropriate &lt;/del&gt;use vigabatrin while &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;people &lt;/del&gt;are dealt with. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;It &lt;/del&gt;is not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;feasible &lt;/del&gt;for your healthcare &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;provider &lt;/del&gt;to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;understand when vision loss will certainly happen&lt;/del&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;It is &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;advised &lt;/del&gt;that your healthcare provider &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;test &lt;/del&gt;your (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kid&lt;/del&gt;'s) vision prior to or within 4 weeks after beginning SABRIL and &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;a minimum of &lt;/del&gt;every 3 months during treatment until SABRIL is quit. &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Tell &lt;/del&gt;your doctor if you or your youngster have any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;type &lt;/del&gt;of &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;negative &lt;/del&gt;effects that bothers you or that does not &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;disappear&lt;/del&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;If &lt;/del&gt;you are expecting or intend to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;obtain expecting, tell your medical care provider&lt;/del&gt;. If vision &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;screening &lt;/del&gt;can not be done, your healthcare provider &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;may continue suggesting &lt;/del&gt;SABRIL, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;however &lt;/del&gt;will certainly not be able to &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;look for &lt;/del&gt;any &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;type of &lt;/del&gt;vision loss. Your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;medical &lt;/del&gt;care &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;carrier &lt;/del&gt;may &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;stop &lt;/del&gt;suggesting SABRIL for you (or your &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/del&gt;)if vision tests are not done &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;routinely&lt;/del&gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Prior to starting SABRIL, tell your physician concerning every one of &lt;/ins&gt;your (or your youngster&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;'s&lt;/ins&gt;) &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;medical conditions including clinical depression&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;state of mind problems&lt;/ins&gt;, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;self-destructive ideas &lt;/ins&gt;[https://&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;www.symbaloo&lt;/ins&gt;.com/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;embed&lt;/ins&gt;/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;shared/AAAAAlJv5XsAA41_HzbcyQ== &lt;/ins&gt;vigabatrin &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;rems patient enrollment&lt;/ins&gt;] or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;behavior, any type &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;allergic reaction &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SABRIL, vision problems, kidney issues, low red blood cell matters (anemia), and any kind &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mental &lt;/ins&gt;or &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;nervous health problem&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The Vigabatrin REMS Program is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;required &lt;/ins&gt;by the FDA to make certain &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;educated &lt;/ins&gt;risk-benefit &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;choices &lt;/ins&gt;prior to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;initiating &lt;/ins&gt;therapy, and to make &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;sure proper &lt;/ins&gt;use &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;of &lt;/ins&gt;vigabatrin while &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;patients &lt;/ins&gt;are dealt with. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;When vision loss will happen, it &lt;/ins&gt;is not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;possible &lt;/ins&gt;for your healthcare &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;company &lt;/ins&gt;to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;recognize&lt;/ins&gt;. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;It is &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;suggested &lt;/ins&gt;that your healthcare provider &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;examination &lt;/ins&gt;your (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;child&lt;/ins&gt;'s) vision prior to or within 4 weeks after beginning SABRIL and &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;at least &lt;/ins&gt;every 3 months during treatment &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;up &lt;/ins&gt;until SABRIL is quit. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Inform &lt;/ins&gt;your doctor if you or your youngster have any &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;kind &lt;/ins&gt;of &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;adverse &lt;/ins&gt;effects that bothers you or that does not &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;vanish&lt;/ins&gt;.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Inform your healthcare provider if &lt;/ins&gt;you are expecting or intend to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;get expectant&lt;/ins&gt;. If vision &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;testing &lt;/ins&gt;can not be done, your healthcare provider &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;might proceed recommending &lt;/ins&gt;SABRIL, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;but &lt;/ins&gt;will certainly not be able to &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;expect &lt;/ins&gt;any vision loss. Your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;health &lt;/ins&gt;care &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;supplier &lt;/ins&gt;may &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;quit &lt;/ins&gt;suggesting SABRIL for you (or your &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;youngster&lt;/ins&gt;)if vision tests are not done &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;on a regular basis&lt;/ins&gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>BernadetteHornib</name></author>
	</entry>
	<entry>
		<id>http://emdrive.echothis.com/index.php?title=Uses_Side_Impacts_Interactions_Pictures_Warnings_Application.&amp;diff=83408&amp;oldid=prev</id>
		<title>MikeKerry16: Created page with &quot;Tell your healthcare provider immediately if you (or your youngster): may not be seeing as well as before starting SABRIL; start to trip, run across points, or are more awkward than normal [https://atavi.com/share/wpqxlqz14kk1s vigabatrin side effects in babies]; are shocked by things or people coming in front of you that appear to come out of no place; or if your child is acting in different ways than typical.&lt;br&gt;&lt;br&gt;The Vigabatrin REMS Program is called for by the FDA...&quot;</title>
		<link rel="alternate" type="text/html" href="http://emdrive.echothis.com/index.php?title=Uses_Side_Impacts_Interactions_Pictures_Warnings_Application.&amp;diff=83408&amp;oldid=prev"/>
		<updated>2024-06-27T15:54:08Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;Tell your healthcare provider immediately if you (or your youngster): may not be seeing as well as before starting SABRIL; start to trip, run across points, or are more awkward than normal [https://atavi.com/share/wpqxlqz14kk1s vigabatrin side effects in babies]; are shocked by things or people coming in front of you that appear to come out of no place; or if your child is acting in different ways than typical.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The Vigabatrin REMS Program is called for by the FDA...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Tell your healthcare provider immediately if you (or your youngster): may not be seeing as well as before starting SABRIL; start to trip, run across points, or are more awkward than normal [https://atavi.com/share/wpqxlqz14kk1s vigabatrin side effects in babies]; are shocked by things or people coming in front of you that appear to come out of no place; or if your child is acting in different ways than typical.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The Vigabatrin REMS Program is called for by the FDA to make certain informed risk-benefit decisions prior to launching therapy, and to make certain appropriate use vigabatrin while people are dealt with. It is not feasible for your healthcare provider to understand when vision loss will certainly happen. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;It is advised that your healthcare provider test your (or your kid's) vision prior to or within 4 weeks after beginning SABRIL and a minimum of every 3 months during treatment until SABRIL is quit. Tell your doctor if you or your youngster have any type of negative effects that bothers you or that does not disappear.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;If you are expecting or intend to obtain expecting, tell your medical care provider. If vision screening can not be done, your healthcare provider may continue suggesting SABRIL, however will certainly not be able to look for any type of vision loss. Your medical care carrier may stop suggesting SABRIL for you (or your child)if vision tests are not done routinely.&lt;/div&gt;</summary>
		<author><name>MikeKerry16</name></author>
	</entry>
</feed>